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A B S T R A C T
The human DEAD-box RNA helicase DDX3 has been implicated to play a role in the whole repertoire of
processes regulating gene expression, including transcription, splicing, mRNA export and translation. It
has also been suggested to be involved in cell cycle control and the regulation of apoptosis. In addition,
DDX3 was recently shown to be part of innate immune signalling pathways and to contribute to the
induction of anti-viral mediators, such as type I interferon. Interestingly, DDX3 appears to be a prime
target for viral manipulation: at least four different viruses, namely Hepatitis C virus (HCV), Hepatitis B
virus (HBV), Human Immunodeficiency Virus (HIV) and poxviruses, encode proteins that interact with
DDX3 andmodulate its function. HIV and HCV seem to co-opt DDX3 and require it for their replication. It
has therefore been suggested that DDX3 could be a novel target for the development of drugs against
these two viruses, both of which still pose major global health threats. However, in the light of the
apparent multifunctionality of DDX3 in the cell, drug development strategies targeting DDX3 will have
to be carefully evaluated. This review summarises the available data on the cellular functions of DDX3
and discusses their manipulation by the different viruses known to target DDX3. Understanding the viral
strategies for manipulating or co-opting DDX3 in functional and molecular detail can provide valuable
insights for the development of strategies to therapeutically target DDX3.
 2009 Elsevier Inc. All rights reserved.
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DDX3 (or DBX) is a member of the DEAD-box family of putative
RNA helicases. It was first identified in 1997 as one of five X-
chromosomal genes that have homologues in the non-recombin-
ing region of the Y-chromosome (DBY, DDX3Y) [1]. The DDX3 (or
more correctly DDX3X) gene escapes X-inactivation [1] and isAbbreviations: 4eBP, eIF4e-binding protein; aa, amino acid; Cdc, cell division cycle;
CRM-1, chromosome maintenance region-1; DDX3, DEAD-box protein 3; eIF,
eukaryotic initiation factor; EJC, Exon junction complex; GSK, glycogen synthase
kinase; HBV, Hepatitis B virus; HCC, hepatocellular carcinoma; HCV, Hepatitis C
virus; HIV, Human Immunodeficiency Virus; HLA, human leukocyte antigen; IAP,
inhibitor of apoptosis; IFN, interferon; IkB, inhibitor of nuclear factor-kB; IKK, IB-
kinase; IRES, internal ribosome entry site; IRF, interferon regulatory factorMAVS-
mitochondrial antiviral signalling; mRNA, messenger RNA; NES, nuclear export
signal; NPC, nuclear pore complex; NS3/4a, non-structural 3/4a; PABP, polyA-
binding protein; PRR, pattern recognition receptor; RIG, retinoic-acid inducible
gene; RLH, RIG-like helicase; RNP, ribonucleoprotein; rRNA, ribosomal RNA; siRNA,
small interfering RNA; snRNA, small nuclear RNA; Sp1, specificity protein 1; TAP,
tip-associated protein; TBK, TANK-binding kinase; TLR, Toll-like receptor; TRAIL-R,
TNF-related apoptosis-inducing ligand-receptor; TRIF, TIR-domain containing
adaptor inducing IFNb; UTR, untranslated region; VACV, vaccinia virus.
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doi:10.1016/j.bcp.2009.08.032ubiquitously expressed in a wide range of tissues [2]. DEAD-box
helicases are involved in a large variety of cellular processes
involving RNA, such as splicing, mRNA export, transcriptional and
translational regulation, RNA decay and ribosome biogenesis [3]. In
recent years, DDX3 has received a lot of interest because of several
studies showing its manipulation by viruses that posemajor global
health threats, such as Human Immunodeficiency Virus (HIV) [4],
Hepatitis C virus (HCV) [5–8] and poxviruses [9]. Due to the finding
that HIV and HCV seem to require DDX3 for their replication [4,8],
the inhibition of DDX3 has been suggested as a novel therapeutic
strategy for the development of drugs against these viruses [10].
However, it was recently demonstrated that DDX3 is also involved
in the induction of anti-viral mediators [9,11] and it appears to
function in protein translation, cell cycle control and apoptosis.
Therefore, it seems crucial to understand how exactly DDX3
contributes to these processes in order to design informed
strategies for its inhibition or manipulation. This review focuses
in particular on the viral manipulation of DDX3 and discusses
which cellular functions of DDX3 are targeted by the virus. Inmany
cases, studying a viral protein and its host targets has provided
novel insights about the function of the host target. For example,
this was also the case with vaccinia virus protein (VACV) K7 which
revealed a novel role for DDX3 in anti-viral immunity [9].
Therefore, it has been and will be a valuable approach to deduce
information about DDX3 function from the way viruses are
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that mimic or prevent the viral strategy to manipulate DDX3
function (see Section 6).
2. Cellular localisation of DDX3
Several studies have described DDX3 as a protein that
constantly shuttles between the cytoplasm and the nucleus, with
its export from the nucleus being mediated by the export shuttle
protein CRM1 [4,9,12]. CRM1 exports proteins containing a
leucine-rich nuclear export signal (NES), and indeed DDX3
contains an NES within its N-terminal 22 amino acids (aa).
However, the association between CRM1 and DDX3 does not seem
to depend on this described NES [4] (discussed further in Section
3.3). More recently, it has been demonstrated that DDX3 can also
be exported via the TAP-dependent export pathway, which
normally mediates the nuclear export of mRNAs [13]. It remains
to be demonstrated whether these two pathways are equally
involved in nuclear export of DDX3, or whether one pathway is
favoured over the other, possibly depending on the cell type or
additional co-factors that associate with DDX3. Presumably due to
the high rate of nuclear export, most studies investigating DDX3
localisation detected it mainly or exclusively in the cytoplasm
[4,6,9,12–14]. DDX3 partially accumulated in the nucleus after
inhibition of CRM1 [4,9,12,13] or TAP [13], suggesting that it can
indeed be exported from the nucleus through both pathways.
In contrast to these results, two other studies found that
endogenous DDX3 was mainly localised in the nuclei of untreated
HeLa cells [5,7]. The reason for this discrepancy is unclear.
However, Chao et al. also demonstrated that DDX3 is mainly
nuclear in healthy primary epidermis cells, but largely cytoplasmic
in skin tissue from cutaneous squamous cell carcinomas [15],
suggesting a difference between transformed and non-trans-
formed cells. It is conceivable that nuclear import and export of
DDX3 are regulated; however the mechanisms for this have yet to
be uncovered. For example, post-translational modifications could
modulate either process, or DDX3 could be retained in the nucleus
through the association with nuclear proteins. As the various
described cellular functions of DDX3 include both cytoplasmic and
nuclear processes (for example translational and transcriptional
regulation, respectively), nuclear-cytoplasmic shuttling of DDX3
might be closely linked to its participation in these processes. In
particular, DDX3 might be regulating or mediating nuclear export
ofmRNAs through its associationwith the nuclear export receptors
(discussed in more detail in Section 3.3).
3. The role of DDX3 in RNA metabolism
DEAD-box helicases are involved in all aspects of RNA
metabolism. Their role is thought to be the unwinding of RNA,
i.e. the removal of secondary structure motifs, the unwinding of
short RNA–RNA interactions and also the removal of RNA-bound
proteins. All DEAD-box helicases contain nine conserved helicase
motifs, including the eponymous Asp–Glu–Ala–Asp (D-E-A-D)
motif, within a structurally conserved core element forming two
recA-like domains. The conserved helicase motifs are involved in
ATP binding, ATPase activity, RNA substrate binding and unwind-
ing. However, the N- and C-termini of DEAD-box helicases are
much more divergent and thought to confer functional specificity
to individual DEAD-box helicases [3].
3.1. Unwinding of RNA
Ded1p, the yeast homologue of DDX3, appears to unwind RNA
duplexes (and interestingly DNA–RNA duplexes) in a mode
different from canonical translocating helicases [16]. Translocatinghelicases, e.g. DNA helicases, move along one strand of RNA or DNA
directionally and in an energy-dependent manner. In the process,
they displace complementary nucleic acid strands and/or inter-
acting proteins.
However, Ded1p unwinds substrates without strict polarity.
Based on this and other data, the authors proposed amechanismby
which the separation of the duplex is based on local destabilization
of RNA helical regions, meaning that the helicase sitting on the
duplex RNA ‘switches’ the two strands apart [16]. This would be a
suitable mechanism for DEAD-box helicases, since they mainly
appear to be involved in local structural changes of RNA and
ribonucleoprotein (RNP) complexes, involving only a small
number of base pairs [16,17]. It is possible that this mechanism
distinguishes DEAD-box helicases from the related RNA helicases
containing DExD- or DEAH-box motifs, some of which have been
shown to be processive RNA helicases [17,18].
3.2. Splicing
Soon after its discovery the yeast Ded1p was linked to splicing
of pre-mRNAs. However, it is still unclear whether Ded1p or
mammalian DDX3 actually contribute to splicing [19]. It has been
suggested that the C-terminus of DDX3 contains a region which
resembles RS-domains found in splicing factors [5]. Ded1p and
DDX3 appear to interact with the spliceosome and mRNPs [20,21]
(Fig. 1A). However, DDX3 tightly associated only with spliced
mRNAs in an Exon junction complex (EJC)-dependentmanner [20].
This would suggest that DDX3 does not have an active role in
splicing, but associates with RNPs after splicing, similar to proteins
of the RNA export machinery.
3.3. Nuclear export of RNA
Several different nuclear transport receptors specifically
mediate the export of proteins and the various classes of RNAs
through the nuclear pore complex. As described in Section 2, DDX3
interacts with two of these export shuttle proteins: CRM1, the
receptor that exports proteins containing a leucine-rich NES, and
TAP, the main mRNA exporter (Fig. 1B). Ribosomal RNAs and small
nuclear RNAs (snRNAs) are also exported in a CRM1-dependent
manner [22].
The mRNA export shuttle protein TAP gets recruited to spliced
mRNAs via the EJC (similar to what was shown for DDX3 [20]). The
interaction between DDX3 and TAP involved the C-terminus of
DDX3 (aa 536–661) [13]. The authors also demonstrated that
DDX3 could be cross-linked to poly(A)-mRNAs in nuclear and
cytoplasmic fractions. Binding of DDX3 to mRNAs was not
disrupted by siRNA-mediated knock-down of TAP, nor did RNAse
treatment disrupt the interaction between DDX3 and TAP [13].
Despite the finding that DDX3 binds to both, mRNAs and TAP, the
authors were unable to show a contribution of DDX3 to polyA-
mRNA export. It therefore seems unlikely that DDX3 is required for
general mRNA export. However, it is still possible that DDX3
participates in the nuclear export of a specific subset of mRNAs via
TAP.
The CRM1–DDX3 interaction is exploited by HIV which seems
to ‘tag’ its incompletely spliced RNAs to the CRM1/DDX3 complex
for export out of the nucleus. This is mediated via an interaction
between the viral RNA-binding protein rev and DDX3 (Fig. 1B).
Hence, DDX3 was shown to be required for the export of HIV RNAs
from the nucleus [4] (further discussed in Section 5.5). However,
the functional relevance of the CRM1–DDX3 interaction in
uninfected cells remains unclear. Yedavalli et al. found that
DDX3 was not required for CRM1-dependent export of proteins
such as IkBa [4], therefore DDX3 does not seem to be a general
cofactor of CRM1. Despite this, the authors postulated that DDX3 is
Fig. 1. DDX3 regulates gene expression at different levels. (A) DDX3 and its yeast homologue have been described to interact with splicing factors and RNPs (see Section 3.2).
(B) DDX3 can be exported from the nucleus by the CRM1 and the TAP export shuttles, both of which it has been shown to interactwith. The TAP exporter ismainly responsible
for mRNA export from the nucleus and binds to mature RNPs after splicing. DDX3 associates with both TAP and RNPs, but did not seem to be required for bulk mRNA export.
DDX3 also binds to CRM1, which is exploited by HIV. The viral RNA-binding protein rev binds to DDX3 and thereby targets its partially spliced RNAs to the CRM1 export
shuttle for export from the nucleus. Knock-down of DDX3was shown to inhibit HIV replication. The physiological role of the CRM1–DDX3 interaction is unknown (see Section
3.3). (C) DDX3 has been implicated in regulating the initiation of translation. It binds to several translation initiation factors, namely eIF4e, eIF4a, eIF2a, eIF3 and PABP. There
is slightly conflicting data on whether DDX3 has a positive or negative role on translation initiation, as discussed in Section 3.4. (D) DDX3 plays a role in the transcriptional
regulation of gene promoters. It has been shown to downregulate the E-Cadherin promoter, while it enhances IFNb and p21waf promoter induction. It is likely to be recruited
to gene promoters by other transcription factors or co-activators (discussed in Section 3.5). The different steps in the gene expression process are tightly coordinated and it is
possible that DDX3 serves as an integrating factor, accompanying anmRNA along theway from transcription to translation. In the online colour version of this figure, proteins
that have been shown to interact with DDX3 are depicted in blue. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version
of the article.)
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This was based on their finding that DDX3 binding to CRM1 was
Ran-GTP independent and did not require the NES of DDX3. Rather,
the CRM1 interaction was mediated by aa 260–517 of DDX3 [4].
One possibility is that DDX3 mediates the export of specific RNAs
through the CRM1 pathway. If DDX3 was needed for the export of
snRNA via CRM1 it could indirectly have an effect on splicing by
affecting the maturation of snRNAs, which are exported from and
re-imported into the nucleus before they assemble with other
splicing factors into a functional spliceosome [22]. Also, a small
subset of inducible mRNAs, including IFNa1 mRNA and IFNg-
induced HLA-A mRNA [23,24] is exported by CRM1 rather than
TAP. Given its recently identified role in anti-viral gene expression
[9] (further discussed in Sections 3.5 and 5.1), it is tempting to
speculate that DDX3 might have a role in mediating the export of
these and other immuno-relevant mRNAs.
3.4. Protein translation
The S. cerevisiae homologues of DDX3, Ded1p and Dbp1p,
function in translation initiation [19]. There is evidence that
Ded1p is required (in addition to the DEAD-box containingtranslation initation factor eIF4a) for the unwinding of 50
untranslated regions (UTRs), with Ded1p being faster and more
efficient in the scanning of long 50UTRs than eIF4a [25,26]. It was
shown that human DDX3 can substitute for Ded1p in genetic
complementation studies, suggesting that the human protein also
facilitates translation initiation. It was demonstrated that DDX3
interacts with several translation initiation factors, namely eIF4e
[27], eIF4a, eIF2a, PABP [13] and eIF3 [14] (Fig. 1C). However, in
one of the initial studies, human DDX3 was described to be a
repressor rather than a facilitator of cap-dependent protein
translation while it enhanced IRES-dependent viral protein
translation: DDX3 was shown to interact with eIF4e and to
prevent the recruitment of eIF4G to eIF4e, which is required for
the initiation of cap-dependent translation [27]. The authors
suggested that DDX3 acts like cellular eIF4e-binding proteins
(4eBPs) which also prevent translation initiation [27]. Never-
theless, there is now more data supporting a positive role of
humanDDX3 in translation initiation:One studydemonstrated an
interaction with eIF3 and a positive role for DDX3 in the
translation of a b-globin mRNA [14]. Another study did not reveal
an effect of DDX3 shRNA knock-down on global protein
translation levels in pulse-labelling experiments, but showed
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mRNAs containing complex secondary structures in their 50UTRs
[13],which is reminiscent of thedatadiscussedabove for the yeast
Ded1p. A DDX3 mutant lacking helicase activity (S382L) [4] was
unable to facilitate translation of highly structured mRNAs,
suggesting that DDX3 is required to unwind the complex
secondary structures of these mRNAs to allow for efficient
translation [13]. Taken together, there appears to be more
evidence for a positive role of DDX3 in protein translation.
However, DDX3 was also found to associate with cytoplasmic
stress granules, which are formed in cells after exposure to
environmental stress and contain stalled translation pre-initia-
tion complexes [13]. It is possible that the level of DDX3
expression influences whether it has a positive or negative effect
on translation, given that the study characterising DDX3 as a
translational repressor was based on overexpressed DDX3 [27].
This finding could be explained if the role of DDX3 was to bridge
interactions between two or more proteins required for transla-
tion initiation. In this case, an excess of DDX3 would saturate the
binding sites andprevent formation of themulti-protein complex,
leading to inhibition rather than enhancement of translation. It is
also possible that DDX3 affects the translation of specific mRNAs
differentially. In the context of DDX3 being a target for viral
manipulation, it would be interesting to clarify whether there are
indeed differences between cap-dependent (cellular) and IRES-
dependent (viral) translation, and whether mRNAs with more
complex 50UTRs are in fact more dependent on DDX3. It has
recently been shown that the mRNA of a transcription factor
essential for type I interferon production, IRF7, contains a highly
structured 50UTR and that its translation is repressed by 4eBP1/2,
thereby putting type I IFN production under translational control
[28]. Like in the case of mRNA export, it is intriguing to speculate
that DDX3 specifically enhances translation of IRF7 and other
immuno-relevant genes.
3.5. Transcriptional regulation
There is increasing evidence that DExD/H RNA helicases can
also function in transcriptional regulation of gene promoters,
complementing their repertoire of regulatory functions in gene
expression. Interestingly, this function often does not require
ATPase or helicase activity, making DExD/H proteins truly
multifunctional [29]. For DDX3 in particular, there is evidence
that it can regulate transcription. It has been shownby chromatin-
immunoprecipitation experiments to associate with the E-
Cadherin and the IFNb promoter. Promoter activation was
upregulated by DDX3 in the case of the IFNb promoter [9,11]
and downregulated in the case of the E-Cadherin promoter [30]. In
addition, it has been demonstrated that DDX3 can bind to the
transcription factor Sp1 and enhance the p21waf promoter in an
Sp1-dependent manner [15] (Fig. 1D). It will have to be
determined in more detail how DDX3 gets recruited to specific
promoters. Even thoughDDX3was initially suggested to contain a
leucine-zipper [2], there is little substantiation for the existence of
this motif in DDX3 and an ability to bind to specific DNA
sequences. It is more likely that DDX3 gets recruited to specific
promoters by interacting with promoter-specific transcription
factors or other co-activators, as seems to be the case for the
p21waf promoter [15]. The recruitment of DDX3 to the IFNb
promoter appeared to be independent of IRF3 [11], but it is
possible that DDX3 recruitment is mediated by a transcription
factor other than IRF3 in this case. Other DExD/H familymembers,
such as DHX9, DDX5 and DDX17, have been shown to bridge
interactions between transcription factors and co-activators and/
or RNA polymerase II [29] and it will be interesting to seewhether
DDX3 functions in a similarmanner. Another interesting questionis whether the role of DDX3 in gene promoter regulation is
dependent on its helicase activity. The effect of DDX3 on the IFNb
promoter was independent of its ATPase or unwinding activity,
since the K230E mutant of DDX3, which has been shown to lose
both functions [4], behaved like wild-type DDX3 [9,11]. On the
other hand, the effect of DDX3 on the p21waf promoter appeared
to require ATPase but not unwinding activity [15]. It is therefore
possible that DDX3 regulates individual promoters in slightly
different ways and future studies should reveal the exact
mechanism(s) bywhichDDX3 regulates gene promoter activation
and/or suppression. Likewise, it is unlikely that the full range of
promoters that are affected by DDX3 has been discovered, and it
will be interesting to see how specific or wide-spread the role of
DDX3 in transcriptional regulation is. In particular, if DDX3 is
taken forward as a therapeutic target, it will be important to
determine the extent of its involvement in gene regulation.
3.6. Conclusion: role of DDX3 in the regulation of gene expression
As discussed in Sections 3.2–3.5, there is evidence for a role of
DDX3 in every step of gene expression: transcription, mRNA
maturation, mRNA export and translation (Fig. 1). These processes
are tightly coordinated, and it is an attractive thought that DDX3
might be involved in integrating these processes to ensure efficient
progression of an mRNA through the route from transcription to
translation. Since several studies failed to show a role for DDX3 in
bulk mRNA export or general protein synthesis, this function of
DDX3 might be specific for a subset of mRNAs.
4. DDX3 in cell cycle control, apoptosis and tumourigenesis
There is mounting evidence of a role for DDX3 in cell cycle and
cell growth control. The data, however, is ambiguous in that
DDX3 has been suggested to be both a tumour suppressor [15,31]
and an oncogene [30]. This conflicting data might point to cell-
type specific differences or could be linked to the slightly
ambiguous role of DDX3 in protein translation, where an excess
of DDX3 appeared to inhibit rather than enhance translation
[13,27].
4.1. Tumour suppressor function of DDX3
It has been shown that DDX3 expression is downregulated in
human hepatocarcinoma (HCC) samples, in particular those of
male patients and Hepatitis B virus (HBV)-positive patients. It was
suggested that lower DDX3 protein levels could contribute to the
three times higher prevalence of HCC in men and HBV-induced
cellular transformation. Hence, it was postulated that DDX3 acts as
a tumour suppressor [15,31]. The authors also showed that siRNA-
mediated knock-down in the non-transformed murine fibroblast
cell line NIH3T3 led to a premature entry into S phase and an
increase in cell proliferation [31]. This correlated with lower levels
of p21waf and elevated levels of CyclinD1 in the DDX3 knock-
down cells [31]. Interestingly, the authors showed that the loss of
DDX3 was insufficient for cellular transformation, but the
combined loss of DDX3 and overexpression of the oncogene v-
ras led to enhanced transformation of NIH3T3 cells. In a follow-up
study, it was demonstrated that DDX3 upregulates the p21waf
promoter in an Sp-1 dependent manner [15] (also discussed in
Section 3.5). The authors showed evidence that ectopic expression
of DDX3 can inhibit proliferation of tumour cell lines (HCT116,
HeLa, HuH-7) and non-transformed cell lines (NIH3T3). This effect
of DDX3 was drastically reduced in HCT116 cells lacking p21
expression, suggesting that DDX3 indeed exerts its effect on cell
proliferation in a p21-dependent manner [15]. In contrast to these
two studies, an earlier study suggested that DDX3 mRNA
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[32]. The reason for this discrepancy is unclear, however it was
suggested that it might relate to differential regulation at mRNA
and protein level [31]. It will be interesting to determine the exact
relationship between DDX3 and p21 and its influence on cell cycle
control.
Further evidence for a link between DDX3 and cell cycle control
is provided by studies on hamster DDX3 [12,33]: DDX3 appears to
influence the levels of the cell cycle regulator Cyclin A and to be
phosphorylated by Cyclin B/cdc2 during mitosis [12,33].
In addition, Hamster tsET24 cells, which are temperature
sensitive cells with a point mutation in DDX3 (P267S), exhibit G1
arrest at the non-permissive temperature [34]. The residues
phosphorylated by cdc2, most importantly Thr204, sit within
conserved helicase motifs of DDX3 and are therefore likely to
disrupt substrate binding and helicase activity [33,35]. It is
possible that this is linked to reduced protein translation during
mitosis, provided that a role for DDX3 in general protein
translation can be substantiated. Further clarification is needed
as to how DDX3 function is affected by the cdc2-dependent
phosphorylation. It is also unclear how DDX3 contributes to the
decrease in Cyclin A levels.
Some of the described studies have initially been inspired by
the finding that Hepatitis C virus core protein interacts with DDX3
(discussed in Section 5.3) and future studies should clarifywhether
and how the core protein of HCV (which has been shown to
contribute to cellular transformation) affects the role of DDX3 in
cell cycle control.
4.2. DDX3 as an oncogene
It has been suggested that DDX3 has an oncogenic role in breast
cancer biogenesis [30]. The study showed that benzo[a]pyrene diol
epoxide (BPDE), a cancer-causing compound found in tobacco
smoke, increases levels of DDX3 expression in an immortalized
non-tumourigenic human breast epithelial cell line (MCF 10A
cells). The authors also demonstrate that DDX3 protein and mRNA
levels positively correlate with tumourigenicity of breast epithelial
cell lines, suggesting that aggressive breast cancer cell lines have
higher levels of DDX3 protein [30]. MCF 10A cells stably
overexpressing DDX3 showed an increase in anchorage-indepen-
dent growth, motility and invasion, which is indicative of cellular
transformation [30]. Loss of E-Cadherin, which is an adhesion
molecule mediating cell-cell contact, has been shown to induce
epithelial–mesenchymal transition in several cancers [36]. Hence,
the authors tested whether DDX3 overexpression or knock-down
affected E-Cadherin expression and demonstrated that DDX3
suppresses the E-Cadherin promoter [30] (see also Section 3.5). In
contrast to Yan Wu Lee’s laboratory [15,31], the authors did not
find a correlation between DDX3 and p21 protein levels in breast
epithelial cells and were unable to see upregulation of a p21
promoter reporter construct by DDX3 [30]. Again, it is quite
unclear what causes this discrepancy, unless one assumes that the
effect of DDX3 on the p21 promoter is cell-type specific. It is certain
that DDX3 is only one of many regulatory factors influencing cell
proliferation and cellular transformation, so the overall outcome of
enhanced or reduced DDX3 levels might depend on the presence/
absence of other co-factors and the activation of signalling
pathways.
4.3. DDX3 and apoptosis
The development of cancer can be linked to enhanced cell
proliferation and/or reduced levels of programmed cell death
(apoptosis). So far, there is only little data regarding a role for DDX3
in apoptosis and further studies will be needed to clarify this.Chang et al. reported preliminary data that Caspase 6 and -9 cannot
be activated in the absence of DDX3, hence protecting DDX3
knock-down cells from apoptosis [31]. Their data therefore suggest
that loss of DDX3 leads to enhanced cellular proliferation and
reduced apoptosis, both features that promote tumourigenesis
[31]. In contrast, the only study dedicated to a role for DDX3 in
apoptosis describes an anti-apoptotic role for DDX3 [37]. The
authors identified an anti-apoptotic complex consisting of GSK3,
DDX3 and c-IAP1, which binds to death receptors and prevents
signalling. Death receptor stimulation led to inactivation of GSK3
and caspase-dependent cleavage of c-IAP1 and DDX3 [37]. The
exact role of DDX3 in this complex is unclear. However, knock-
down of DDX3 enhanced signalling through the death receptor
TRAIL-R2 and activation of caspase 3 [37].
In the light of the limited amount of data on the role of DDX3 in
apoptosis, there is scope for further studies to clarify this
potentially important function of DDX3. The possibility that
DDX3 differentially affects intrinsic and extrinsic apoptotic
signalling pathways should be considered. Signalling by death
receptors requires assembly of the death inducing signalling
complex (DISC) comprising the initiator caspase 8. The intrinsic or
mitochondrial pathway is regulated, e.g. by Bcl-2 family proteins
and involves the initiator caspase 9. The data summarised above
seems to suggest that DDX3 is required for activation of the
intrinsic pathway [31], but downregulates activation of the
extrinsic pathway [37]. However, this appears to make limited
physiological sense, so clarification of the role of DDX3 in apoptosis
is needed and should be addressed in further studies.
4.4. Conclusion: DDX3 in tumourigenesis
The data available on the role of DDX3 in cell cycle regulation,
cellular transformation and apoptosis is still rather limited, so
further studies should bring clarification and additional mechan-
istic insight into the involvement of DDX3 into these processes.
Due to itsmultifunctionality, it is possible that DDX3 can have both
positive and negative effects on cell proliferation depending on the
cell type and environmental conditions. It will be important to
understand and reconcile these effects of DDX3 on cellular events
contributing to tumourigenesis, before DDX3 can be explored as a
therapeutic target for viral infections and autoimmune diseases
(further discussed in Sections 5.5 and 6).
5. DDX3 as a target of viral manipulation
One of the most intriguing features of DDX3 is its manipulation
by viruses. Because viruses have limited genome sizes and are
highly optimized through evolution, they tend to target key
regulators within the host cell machinery to help them replicate.
On the one hand, this comprises recruitment of host factors, such
as transcription factors or polymerases, that directly participate in
replication of the virus. On the other hand, a lot of viruses encode
immunoregulatory proteins that inhibit or modulate the immune
response, so that the virus can either avoid detection by the
immune system altogether or interfere with the ensuing signalling
pathways leading to cytokine expression. In particular, a lot of
viruses have evolved mechanisms to inhibit the induction or
function of type I interferons (IFN), potent anti-viralmediators that
were named after their ‘interfering’ effect on viral replication [38].
DDX3 has recently been shown to contribute to IFNb production
downstream of pattern recognition receptor activation [9,11]. This
would make it a potential target for viral evasion strategies aimed
at the IFN pathway, and indeed, we have shown that the poxvirus
protein K7 targets DDX3 and interferes with IFNb promoter
activation [9]. On the other hand, HIV andHCV depend onDDX3 for
their replication, exploiting its nuclear export and helicase
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However, it is possible that some viruses recruit DDX3 to helpwith
replication of the viral genome while simultaneously sequestering
and preventing DDX3 from inducing type I IFNs, meaning that
these viruses would get dual benefit from their interaction with
DDX3.
5.1. DDX3 participates in innate immune signalling and enhances the
induction of anti-viral mediators.
We and others have recently described a positive role for DDX3
in the induction of IFNb, revealing an unexpected function of DDX3
in anti-viral gene expression [9,11].
Viral recognition by the innate immune system is mediated by
different classes of pattern recognition receptors (PRRs): The
subset of endosomal Toll-like receptors (TLRs) that comprises
TLR3, TLR7, TLR8 and TLR9 recognises the different classes of viral
nucleic acids within the lumen of the endosome. On the other
hand, RIG-like helicases (RLH) (RNA helicases belonging to the
DExH family) recognise viral RNAs in the cytoplasm of cells [39].
Both sets of anti-viral PRRs lead to the activation of the
transcription factors NF-kB and Interferon regulatory factors
(IRF)3 and IRF7, which are required for IFNb promoter induction.
IKKe and the related kinase TBK1 are required for the phosphor-
ylation-induced activation of IRF3 and IRF7 downstream of most
anti-viral PRRs (TLR3, TLR4 and the RLHs).We have recently shown
that DDX3 interacts with IKKe after Sendai virus infection, and
contributes to IRF3 activation and IFNb and promoter activationFig. 2. The role of DDX3 in innate immune signalling. DDX3was shown to interactwith an
transiently induced during Sendai virus infection, linking DDX3 into the signalling p
recognition) to IRF3 activation and IFNb promoter activation (Section 5.1). IKKe and TBK
such as TLR3 and TLR4, and consequently DDX3 also enhanced IFNb promoter induction d
enhancer, suggesting that it acts as a transcriptional co-activator (Sections 3.5 and 5.1). Th
required for IFNb promoter induction. K7 is a potent inhibitor of IRF3 activation and IFNb
its effect on IFN induction (Section 5.2). In the online colour version of this figure, p
interpretation of the references to colour in this figure legend, the reader is referred to(Fig. 2) [9]. This novel role of DDX3 in anti-viral innate immune
signalling was simultaneously described in another study identi-
fying DDX3 as a TBK1-interacting protein and phosphorylation
target [11]. In accordance with our data, the authors also
demonstrated that knock-down of endogenous DDX3 by siRNAs
reduced IFNb promoter induction downstream of different PRRs
[11]. Both studies agree that ATPase and helicase function of DDX3
are dispensable for the effect of DDX3 on the IFNb promoter,
showing that a mutation in the Walker A motif (K230E) of DDX3
does not affect this function of DDX3 [9,11] (see Section 3.5).
Using a series of truncation mutants, we showed that the N-
terminus of DDX3 is required for its effect on the IFNb promoter,
since truncations lacking the first 139 aa were unable to mediate
promoter induction [9]. Soulat et al. identified several serine/
threonine residues within the two recA-like domains of DDX3
(between aa 181 and aa 543) as TBK1-phosphorylation sites, and
showed that S/T! A mutation of putative TBK1-phosphorylation
motifs contained within either recA-like domain of DDX3 led to a
decrease in IFNb promoter induction [11]. They also demonstrated
by chromatin immunoprecipitation that DDX3 bound to the IFNb
promoter enhancer region (with no requirement for IRF3) [11].
Their data suggest that DDX3 acts as a transcriptional co-factor
that is activated by TBK1-phosphorylation, much in the same way
as IRF3 and IRF7 themselves. Apart from the IFNb promoter, there
is further evidence that DDX3 can bind to and regulate gene
promoters, as discussed in Section 3.5.
The exact molecular detail of how DDX3 contributes to IRF3
activation and IFNb promoter activation remains to be elucidated,d be phosphorylated by TBK1 and IKKe. The interaction betweenDDX3 and IKKewas
athway from RIG-I (the pattern recognition receptor that mediates Sendai virus
1 also mediate IRF3 activation downstream of other pattern recognition receptors,
ownstream of these receptors. DDX3was found to associatewith the IFNb promoter
e vaccinia virus protein K7 binds to the N-terminus of DDX3, whichwas found to be
promoter induction. This suggests that K7 binding toDDX3 prevents it from exerting
roteins that have been shown to interact with DDX3 are depicted in blue. (For
the web version of the article.)
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TBK1/IKKe is currently unclear.
5.2. Poxvirus protein K7 targets DDX3 to inhibit anti-viral gene
expression
We have recently identified the vaccinia virus (VACV) protein
K7 as a viral protein that interacts with DDX3 and inhibits its
function in the IFN induction pathway [9]. The potent inhibitory
effect of K7 on TLR-and RLH-dependent IRF3/7 activation and IFNb
promoter induction led us to investigate a potential role of its host
target DDX3 in this innate immune signalling pathway [9].
Interestingly, K7 binds to the N-terminal region of DDX3 (aa 1–
139) that we found to be required for the effect on the IFNb
promoter [9]. It is therefore conceivable that binding of K7 to this
region of DDX3 prevents downstream signalling (Fig. 2). In a more
recent study, we have narrowed down the K7-DDX3 binding site to
the region between aa 61–90 of DDX3 [40].
The N-terminus of DDX3 contains several other interesting
motifs, including the NES (see Section 2) [4] and the potential eIF4e
interaction site (aa 38–43) (see Section 3.4) [27]. Unfortunately,
the N-terminus of DDX3 also appears to be highly flexible and is
missing in the available crystal structure of DDX3 [35], so that we
have no structural information about this functionally important
region of DDX3.
We will continue to explore the molecular detail and nature of
the interaction between K7 and DDX3 with the aim of under-
standing how poxviruses manipulate DDX3, and how the region of
DDX3 targeted by K7 contributes to the cellular functions of DDX3.
5.3. DDX3 interacts with HCV Core protein and is required
for HCV replication
HCV core protein was the first viral protein to be described as a
DDX3-interacting protein. HCV core protein is a structural protein,
which forms the viral nucleocapsid. However, there is evidence
that the core protein has other functions, e.g. it has been described
to modulate viral and cellular gene expression. Three independent
publications described the interaction between DDX3 and HCV
core protein; however their studieswere hampered by limited data
being available on the cellular function of DDX3 at the time of
discovery. Owsianka et al. mapped the interaction to the C-
terminal serine-rich region of DDX3 (aa 553–622), which they
suggested to resemble RS-domains found in splicing factors. They
also found DDX3 associated with nuclear speckles, and therefore
suggested that DDX3 plays a role in splicing [5]. Expression of HCV
core protein, however, did not affect the localisation of DDX3 to
nuclear speckles. In contrast, it affected the distribution of the
cytoplasmic fraction of DDX3 and led to strong co-localisation of
DDX3 and core protein in distinct spots in the cytoplasm,
suggesting that the core protein targets a cytoplasmic function
of DDX3 [5]. Yan-Hwa Wu Lee’s group also identified the
interaction between HCV Core protein and DDX3, which they
initially called Cap-Rf (Core-associated protein-RNA helicase full-
length) and believed to be distinct from, but closely related to,
DDX3. They also mapped the interaction to the C-terminal region
of DDX3 (aa 473–611). In addition, they showed that addition of
recombinant core protein enhanced the ATPase activity of DDX3
[7]. In their study, DDX3 expression also induced expression of a
luciferase reporter construct, pCMV-luc, and co-expression of HCV
core protein further enhanced the induction. This was a first
indication that DDX3 might be involved in transcriptional
regulation of gene promoters (as discussed in Section 3.5), and
furthermore suggested that HCV core protein activates or enhances
DDX3 function [7]. Finally, the third publication describing the
DDX3-Core protein interaction showed that human DDX3 cansubstitute for homologous yeast Ded1p [6]. HCV core protein
negatively affected the growth of DDX3-substituted ded1-deletion
yeast and inhibited the translation of capped, but not un-capped,
RNA in an in vitro translation assay. The authors concluded that
DDX3 functions as an RNA helicase and is involved in translation
initiation of capped RNAs (as discussed in Section 3.4). Their data
suggests indirectly that HCV core protein interferes with this
function of DDX3 [6].
As the evidence is mounting for a role for DDX3 in both
transcriptional and post-transcriptional regulation of gene expres-
sion (see Section 3), cell cycle regulation (see Section 4) and innate
immune signalling (Section 5.1), it appears that DDX3 is a highly
multifunctional cellular protein. It is not completely inconceivable
that HCV core protein could enhance a particular function of DDX3
while simultaneously inhibiting one of its other functions, possibly
explaining some of the diverse findings described above. However,
to date it is not clear what the functional relevance of the DDX3–
Core protein interaction is. It has recently been demonstrated that
DDX3 is required for HCV RNA replication, with genome-length
HCV RNA strongly and subgenomic replicon RNA partially
suppressed in DDX3 knock-down cells [8]. This suggests that
HCV needs DDX3 to aid in the replication of its RNA (possibly by
unwinding double-stranded RNA species), however the exact
contribution of DDX3 remains to be determined. It also does not
explain the core protein–DDX3 interaction, given that the core
protein is not directly involved in viral genome replication.
There is strong epidemiological evidence that chronic HCV
infection is linked to the development of hepatocellular carcino-
mas (HCC), even though themolecularmechanisms underlying the
progression to cancer are not very well defined [41]. It is likely that
immunopathological mechanisms linked to chronic inflammation
play a role, but there is evidence that HCV proteins, including the
core protein, are intrinsically oncogenic [41]. As discussed in
Section 4.2, publications by Wu Lee’s group suggest that DDX3
expression is downregulated in certain hepatocellular carcinomas
(HCC), in particular those occurring in HBV-positive and male
patients [15,27,31]. They also demonstrated that knock-down of
DDX3 with siRNA enhances cell proliferation and downregulates
the expression of the cell cycle regulator p21waf, which appeared
to depend on cooperative action between DDX3 and Sp1 (see
Sections 3.5 and 4.1). This suggested that DDX3 acts as a tumour
suppressor gene by upregulating p21waf levels [15]. The authors
argue that lower levels of DDX3 or functional inactivation of DDX3
might contribute to the development of HCC, potentially explain-
ing the higher rate of HCC in males and the link between HBV and
HCV-infection and HCC [15]. HCV-infection does not appear to
change DDX3 protein levels, however it is possible (though
remains to be demonstrated) that the HCV core protein function-
ally interferes with the effect of DDX3 on the p21waf promoter.
As discussed above, some viruses might benefit from DDX3
sequestration in two different ways, one being the disruption of
signalling pathways leading to IFNb promoter activation. Upon
introduction of HCV core protein into cells, a striking re-
distribution of DDX3 occurs from a diffuse cytoplasmic localization
into distinct cytoplasmic spots co-localised with HCV core protein
[5]. This may suggest that the HCV core protein sequesters DDX3
from some of its cellular functions, such as IFNb promoter
activation, by pulling it into these cytoplasmic complexes. On the
other hand, HCV has other extremely potent mechanisms for
inhibiting IRF3 activation and IFNb induction, e.g. the cleaving of
the signalling adaptors TRIF andMAVS by the viral protease NS3/4a
[42]; hence inhibition of DDX3might be unnecessary or redundant
for HCV.
For lack of experimental data, the functional consequences of
the HCV core protein–DDX3 interaction remain mysterious and
further research is required to investigate whether and how the
Table 1
Interaction of DDX3 with viruses.
Virus Effect of DDX3
on viral replication
Viral interacting
protein
Cellular function
of DDX3 targeted
Helicase activity
required
Therapeutic
potential
References
HCV + Core Translation? p21 promoter
activation? Helicase function?
? Inhibit DDX3 function in
HCV replication.
[5–8]
HBV  HBV Pol ? ATPase: Yes
Helicase: No
[43]
HIV + rev Nuclear-cytoplasmic shuttling Yes Inhibit helicase activity,
Inhibit nuclear-cytoplasmic shuttling?
[4,44–46]
VACV ()a K7 IFNb promoter induction No Use K7 mimetics to inhibit DDX3
in IFN-dependent autoimmune disorders.
[9,40]
a Has not been determined. K7 inhibits role of DDX3 in IFNb induction, hence role of DDX3 appears to be antiviral.
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DDX3. It is important to determine whether this interaction
contributes to viral replication, persistence and/or the develop-
ment of virus-induced carcinomas.
5.4. DDX3 inhibits HBV replication
Hepatitis B virus is the prototypic member of the hepadnavirus
family. Replication of the genome occurs by reverse transcription
of the pregenomic RNA template, is mediated by the HBV
polymerase which binds to an RNA stem loop and occurs entirely
within nucleocapsids. It was recently shown that DDX3 binds to
HBV polymerase, in an interaction that did not appear to be
mediated by RNA [43]. DDX3 was incorporated into nucleocapsids
together with HBV polymerase and inhibited the initial step of
reverse transcription in a manner that seemed to depend on the
ATPase-activity of DDX3 [43]. A lot of questions remain
unanswered, such as the exact mechanism of inhibition and the
physiological relevance of the finding. It is interesting that DDX3 is
targeted by two hepatitis viruses, raising the question as to
whether targeting DDX3 might contribute to liver cell tropism
[43]. However, HCV and HBV belong to different virus families and
have different replicationmechanisms,making a common strategy
for targeting DDX3 unlikely. In addition, while DDX3 is required for
HCV replication, it blocks HBV replication. Interestingly, it has been
shown that DDX3 levels are decreased in a fraction of HBV-induced
HCC cases [31]. This could be a viral mechanism to relieve the
inhibitory effect of DDX3 on its replication andmight contribute to
the development of HBV-induced HCC (see Section 4.1).
5.5. DDX3 is required for nuclear export of HIV RNA and viral
replication
In a paper that drew much attention to DDX3, Yedavalli et al.
described a role for DDX3 in HIV replication and suggested it as a
potential therapeutic target for HIV infection [4]. DDX3 was
upregulated in HIV-infected cells in a tat-dependent manner [4].
The authors demonstrated that DDX3 interacts with the HIV rev
protein and the cellular nuclear export protein CRM1. Through the
rev-DDX3 interaction, HIV seems to target its incompletely spliced
mRNAs to CRM1 for export from the nucleus (see Section 3.3).
Downregulation of DDX3 levels in the cell using antisense
technology inhibited the export of partially spliced HIV RNAs
from the nucleus and consequently HIV replication [4]. This
function of DDX3 was dependent on its helicase activity [4], so
DDX3’s role in this process might be the unwinding of secondary
structures within the HIV RNA or the removal of RNA-bound
proteins to facilitate export. In this context, the authors also found
DDX3 to interact with nucleoporins and to localize to the
cytoplasmic side of nuclear pores, which is reminiscent of the
Yeast Dpb5p helicase that functions in nuclear-cytoplasmic export
of mRNAs [4]. Most importantly, it was possible to inhibit HIVreplication by reducing DDX3 protein levels in the cell [4]. The
possibility to exploit the identification of DDX3 as an essential host
factor for HIV replication for the development of novel anti-HIV
therapeutics is exciting, and will be discussed in more detail in
Section 6.1.
5.6. Conclusion: viral manipulation of DDX3
It is highly intriguing that DDX3 is the target ofmanipulation by
at least four very different viruses. Each of the viruses seems to co-
opt or inhibit a different function of the astonishingly multi-
functional DDX3 protein (Table 1); however one has to wonder
whether there is some common denominator that makes DDX3
such an attractive target for viral manipulation. Its newly
discovered role in IFNb promoter induction would lead us to
assume that other viruses, apart from poxviruses, have evolved
mechanisms for inhibiting this particular function of DDX3. As
mentioned before, it is possible that viruses that appear to co-opt
DDX3 also simultaneously inhibit its function in IFNb induction.
Studying these virus–DDX3 interactions inmore detail will provide
us with novel insights into the biology of DDX3 and potentially
lead to the development of anti-viral drugs and the therapeutic
targeting of DDX3 (Table 1).
6. Therapeutic potential
6.1. DDX3 as a target for HIV and HCV therapy
Both, human and viral helicases have been successfully targeted
therapeutically in the past [10]. Given that DDX3 seems to be
required for replication of HCV and HIV, it appears, and was
suggested early on, that DDX3 could be a promising target for drug
development against these two viruses that pose major global
health threats [10]. Targeting a host factor rather than a viral
protein might make it more difficult for a virus to develop
resistance against the drug. On the other hand, DDX3 obviously has
not evolved for the purpose of the virus, and hence one needs to be
careful with the inhibition of a host protein which appears to have
a multitude of cellular functions, none of which has been
elucidated in much detail yet. As described above, tampering
with DDX3 has the potential to affect different levels of gene
expression, cellular proliferation and transformation, and long-
term suppression of DDX3 function could therefore lead to serious
complications, including the development of cancer. However, it
has been shown that knock-down of DDX3 in cells can inhibit HIV
replication without affecting cell viability [44]. In addition, two
studies have been published in which small molecule inhibitors
were used to inhibit the ATPase-activity of DDX3 (which is
required for mediating HIV mRNA export), again without affecting
cell viability or showing toxicity in mouse models [45,46].
However, it is likely that none of these studies would have
revealed effects of DDX3 inhibition on cellular transformation
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activity. Hence inhibiting this enzymatic activity of DDX3 should
leave the ATPase-independent cellular functions of DDX3 intact,
such as the induction of type I IFNs [9,11]. However, it was
suggested that upregulation of the p21waf promoter requires the
ATPase (but not unwinding) activity of DDX3 [15]. This cellular
function of DDX3 is linked to cell cycle control; hence inhibiting
this function carries a risk of contributing to tumourigenesis.
Since DDX3 is also required by HCV for its replication, its
inhibition could also be a valid strategy for the development of
novel HCV drugs. However, even less is known about the exact
molecular mechanisms of the HCV–DDX3 interaction, and there is
evidence linking DDX3 inactivation during virus infection to the
development of liver carcinomas.
The safest strategy would be to develop drugs that very
specifically target the virus–DDX3 interaction. This requires a
detailed understanding of the molecular and functional details of
the interaction and further studies should aim to achieve this.
6.2. Cancer
As discussed in Section 4, current data on the role of DDX3 in
cell cycle control, cellular transformation events and apoptosis is
ambiguous; hence it seems difficult to imagine targeting DDX3 for
cancer therapy at the moment. However, should it emerge in the
future that hyperactivation or inactivation of DDX3 are clearly
linked to certain cancer types, this could lead to the development
of cancer chemotherapies targeting DDX3.
6.3. Autoimmune diseases and viral infections
It has recently been shown that DDX3 seems to have a role in
anti-viral immunity by contributing to type I IFN production [9,11].
Vaccinia virus K7 protein was shown to target this function of
DDX3 in order to inhibit type I IFN production [9]. Since type I IFN
production is a key target of many viral evasion strategies, we will
most likely find that other viruses have evolved similar mechan-
isms to inhibit this particular function of DDX3. Studying these
DDX3–virus interactions could lead to the development of anti-
viral therapeutics, which disrupt the viral strategy and restore
DDX3 function. On the other hand, hyperactivation of the IFN
system, e.g. in autoimmune diseases, could call for therapeutic
inhibition of DDX3 function in this pathway. This could be
achieved by mimicking the viral strategies for interfering with
DDX3 with small molecule inhibitors.
7. Finishing remarks
Even though research on DDX3 has accelerated in recent years
and consequently our knowledge about the cellular functions of
DDX3 has grown, the overall picture still remains fragmentary. It
will be important to resolve the seemingly contradictory data on
the role of DDX3 in cell growth control and the regulation of
protein translation. It should also be attempted to establish
whether the various effects of DDX3 on cellular events are indeed
mediated by independent functions of DDX3, or whether some of
them could be interconnected. Another interesting area of research
will be the regulation of DDX3 activity by post-translational
modification, as there is evidence for DDX3 being phosphorylated
by cdc2, IKKe and TBK1 [11,33]. Most likely, we will also discover
other promoters that are regulated by DDX3 and learn about
additional viral strategies to inhibit or co-opt DDX3. Studying the
manipulation of DDX3 by viruses in detail can provide us with
novel mechanistic insights about the function(s) of DDX3 and
might lead to the development of therapeutics mimicking or
inhibiting the viral strategies.Acknowledgements
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